80% of China’s Clinical Trial Data Fraudulent!

A recent investigation of 1622 new drugs submitted to China’s State Food and Drug Administration (CFDA) has found that 1308 of those applications should be withdrawn for containing fabricated, flawed, or inadequate data from clinical trials. Find out more here. (Source: thebmj, October 2016)

You might also be interested in:

NPC's Dubois: Article's Authors 'Used Flawed Data' March 13, 2019
PAI and BresMed Join Forces to Support Expanded Use of More… July 22, 2019
Pharmerit Expands Market Access Support in Asia January 17, 2019
NPC Disputes ICER Report on Unjustified Price Hikes October 8, 2019
Report: Generic 'Cartel' Probe Expands to 300 Drugs December 10, 2018
Joint Investigation Finds Medical Journals Should Bolster… December 10, 2018
Biomarkers and Companion diagnostics: Payer Insights September 26, 2019